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An efficient synthetic strategy for the synthesis of 6-amino-1-(((2-chloroquinolin-3-yl)methylene)amino)-2-oxo-4-(aryl)-
1,2-dihydropyridine-3,5-dicarbonitriles is well described in this paper. Structures of synthesized compounds have been 
identified by standard spectroscopic techniques like 1H NMR, 13C NMR, IR and mass spectroscopy. Results of the 
biological activity reveals that electron withdrawing groups and presence of –OH group on meta position play a significant 
role for the increment in the antibacterial and antifungal activities respectively of 3a-j. In the present study, it has been 
observed that compounds 3i and 3e are the most active antimicrobials. 
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In recent scenario, bacterial and fungal resistance are 
biggest challenges for the scientific community. 
Microbial infections are causing very harmful effect in 
human body. Due to this, it is necessary to develop new 
hybrid bioactive motifs which may not be resisted by 
microbial strains1. In order to achieve this goal, we have 
made different antimicrobial agents using quinoline and 
2-pyridone skeleton. Quinoline is most potent lead 
structure among the other heterocyclic motifs. It is 
widely used for the treatment of microbial diseases2-13. 
Pyridone nucleus is present in many medicinally 
important alkaloids like “cytisin” which is a tricyclic 
alkaloid in which pyridone nucleus is bind with 
quinolizidine alkaloid14-24. Therefore, our research 
interest is to bind these two active scaffolds in one 
component and to create new set of compounds (3a-j, 
Scheme I) which may not resist by different microbes. 
 
Results and Discussion 
 
Antibacterial assay 
“The newly synthesized compounds were screened 
for their antibacterial activity against Gram-positive 
bacteria (Staphylococcus aureus (MTCC-96), 
Streptococcus pyogenes (MTCC-442) and Gram-
negative bacteria (Escherichia coli (MTCC-443), 
Pseudomonas aeruginosa (MTCC-1688). Antibacterial 
activity was measured as per National Committee for 
Clinical Laboratory Standards (NCCLS) protocol.  
For antibacterial evaluation of newly synthesized 
compounds “Broth dilution method” was used which is 
a widely used technique for in vitro antimicrobial 
evaluation. As a nutrient medium “Muller Hinton Broth” 
has been used to grow the strains and DMSO was used 
as a diluent/vehicle to get the required concentration of 
newly synthesized compounds to test against different 
standard bacterial strains. Ciprofloxacin was used as a 
standard drug for evaluating antibacterial activity, which 
showed 25, 25, 50 and 50 μg/mL MIC against E. coli, 
P. aeruginosa, S. aureus and S. pyogenes respectively. 
Results of in vitro antibacterial screening of 
compounds 3a-j are displayed in Table I. These 
screening results indicate that compound 3i has excellent 
antibacterial potential against E. coli, P. aeruginosa and 
S. aureus bacterial strains with MIC of 12.5 μg/mL. 
Also compound 3i possess very good antibacterial 
activity with MIC of 25 μg/mL against S. pyogenes. 
Compounds 3g, 3h and 3j found to have moderate 
antibacterial efficacy against E. coli strain with MIC of 
150 μg/mL while compound 3j also possessed moderate 
antibacterial potential against P. aeruginosa25. 
 
Antifungal assay 
Newly synthesized compounds which were evaluated 
against different fungal strains. Primary and secondary 
screening was done for antifungal evaluation. Primary 




screening was performed against Candida albicans, 
Aspergillus niger and Aspergillus clavatus at various 
concentrations of 1000, 500, 200 and 100 μg/mL as 
shown in Table I. For stock solution the synthesized 
compounds were diluted up to 1000 µg/mL. Compounds 
which were found to be active in primary screening were 
tested for secondary screening. Griseofulvin was used as 
a standard drug for antifungal activity, which showed 
500, 100 and 100 μg/mL MIC against C. albicans,  
A. niger and A. clavatus respectively”25. Outcome of 
antifungal activity suggested that compound 3e 
exhibited excellent antifungal activity against Candida 
albicans with MIC of 25 μg/mL and moderate 
antibacterial activity against Aspergillusniger and 
Aspergillusclavatus with MIC of 50 μg/mL .Figure 1 
displayed the comparison of the antimicrobial activity. 
 
Structure Activity Relationship Study 
Transparently elucidated from the results of 
antibacterial screening of compounds 3a-j, presence of 
electron-withdrawing groups in compounds 3a-j is 
responsible for enhancing the antibacterial potential. 
Among various functional groups with –I effect, 
presence of –F showed excellent activity against 
bacterial strains. However other electron-withdrawing 
groups i.e. –NO2 and -Cl showed moderate activity 
against Escherichia coli species. As shown in Table I, 
 
 
Scheme I — Synthetic scheme for the preparation of compounds 3a-j 
 
Table I — Results of antibacterial and antifungal activities of compounds 3a-j 
Minimum inhibitory concentration (MIC) µg/mL 
Entry -R Gram-negative Gram-positive Fungi 
  Ec Pa Sa Sp Ca An Ac 
3a -H 250 250 250 250 500 500 500 
3b -4-CH3 250 250 250 250 250 1000 1000 
3c -4-OCH3 250 250 250 250 500 1000 1000 
3d -3,4,5-(OCH3)3 250 500 1000 1000 500 500 500 
3e -3-OH 250 250 500 500 25 50 50 
3f -4-OH 500 500 250 250 500 1000 1000 
3g -3-NO2 150 500 500 1000 1000 500 500 
3h -4-NO2 150 250 250 250 500 500 500 
3i -4-F 12.5 12.5 12.5 25 1000 1000 1000 
3j -2-Cl 150 150 250 250 1000 500 500 
Ciprofloxacin 25 25 50 50 − − − 
Griseofulvin − − − − 500 100 100 
Escherichiacoli (E.c.) MTCC-443; Pseudomonasaeruginosa(P.a.) MTCC-1688; 
Staphylococcusaureus (S.a.) MTCC-96; Staphylococcuspyogenes (S.p.) MTCC-442; 
Candidaalbicans (C.a.) MTCC-227; Aspergillusniger (A.n.) MTCC-282;  
Aspergillusclavatus (A.c.) MTCC- 1323. 
 




among various electron-donating functional groups, 
presence of –OH group on meta position is highly 
responsible for excellent activity against Candida 
albicans, Aspergillus niger and Aspergillus clavatus. 
Comparison of MIC values of compounds 3a-j against 
bacterial and fungal strains using ciprofloxacin and 
griseofulvin as standard drugs are depicted in Figure 1. 
 
Experimental Section 
All reactions except those in aqueous media were 
carried out by standard techniques for the exclusion of 
moisture. Melting points were taken in open glass 
capillary tubes using a Toshniwal melting point 
apparatus and are uncorrected. TLC on silica gel plates 
(Merck, 60, F254) was used for checking homogeneity 
and reaction monitoring. Column chromatography over 
silica gel (Merck, 70-230 mesh and 230-400 mesh 
ASTH for flash chromatography) was applied when 
necessary to isolate and purify the reaction products. 
Elemental analysis (% CHN) was carried out on a 
Perkin-Elmer 2400 CHN analyser. IR spectra of all 
compounds were recorded on a Perkin-Elmer FT-IR 
spectrophotometer in KBr. 1H NMR spectra were 
recorded on a Bruker Advance II 400 MHz and 
13C NMR spectra on Varian Mercury 400 at 100 MHz in 
CDCl3 as a solvent and tetramethylsilane (TMS) as an 
internal standard. Mass spectra were scanned on a 
Shimadzu LC-MS 2010 spectrometer. Anhydrous 
reactions were carried out in oven-dried glass wares in 
nitrogen atmosphere and Büchi Rotavapor instrument 
was used for distillation purpose. 
 
Preparation of 2-chloroquinoline-3-carbaldehyde, 1 
Synthesis of 2-chloroquinoline-3-carbaldehyde was 
achieved by reported literature26. 
Preparation of N'-((2-chloroquinolin-3-yl)methylene)-
2-cyanoacetohydrazide, 2 
The solution of compound 1 was prepared by using 
1,4-dioxane as a solvent, 2-cyanoacetohydrazide was 
added in small portions with stirring in that solution. 
The resulting mixture was refluxed for 1 hour and 
cooled down at RT. The solid separated was filtered 
and recrystallized with the mixture of methanol and 
chloroform. Yield: 90%. m.p. 210°C. IR (KBr): 3435 
(>N-H, stretching), 2243, 2211 (-C≡N, stretching), 
1664 (>C=O, stretching), 756 (-C-Cl, stretching), 
1504 cm−1 (>C=N, stretching); 1H NMR (400 MHZ, 
CDCl3): δ 3.12 (s, 9H, Ar-(OCH3)3, 6.72-8.77 (s, 7H, 
Ar-H), 8.27 (s, 2H, Ar-CH=N-), 8.96 (s, 2H, Ar-
NH2); LCMS: m/z 272.05 (M+). Anal. Calcd for 
C13H9ClN4O C, 57.26; H, 3.33; Cl, 13.00; N, 20.55; 
O, 5.87. Found: C, 57.27; H, 3.34; Cl, 13.01; N, 
20.57; O, 5.84%. 
 




A mixture of compound 2 (0.01 mol), 
corresponding 2-benzylidenemalononitrile (0.01 mol) 
and 2 drops of piperidine in ethanol (99.9%, 50 mL) 
was refluxed for 2-3 h. The mixture was then cooled 
down to RT and the crystals formed were filtered, 




dihydropyridine-3,5-dicarbonitrile, 3a: Yield: 59%. 
m.p. 242°C. IR (KBr): 3436 (>N-H, stretching), 2244, 
 
 
Figure 1 — Comparison of MIC of compounds 3a-j against bacterial and fungal strains 
 




2212 (-C≡N, stretching), 1666 (>C=O, stretching), 
757 (-C-Cl, stretching), 1506 cm−1 (>C=N, 
stretching); 1H NMR (400 MHz, CDCl3): δ 6.71-8.75 
(s, 9H, Ar-H), 8.25 (s, 2H, Ar-CH=N-), 8.94 (s, 2H, 
Ar-NH2); 13C NMR (100 MHz, DMSO-d6): δ 169.4, 
160.0, 159.5, 149.7, 143.2, 137.7, 132.3, 131.2, 128.9, 
128.7 (2), 128.5, 128.2, 127.9, 127.6, 127.1, 126.9, 
125.7, 124.1, 115.6(2), 115.5, 76.5; LCMS: m/z 
424.85 (M+). Anal. Calcd for C23H13ClN6O C, 65.02; 
H, 3.08; Cl, 13.00; N, 19.78; O, 3.77. Found: C, 
64.87; H, 2.89; Cl, 13.01; N, 19.66; O, 3.35%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-2-oxo-4-(p-tolyl)-1,2-
dihydropyridine-3,5-dicarbonitrile, 3b: Yield: 57%. 
m.p. 249°C. IR (KBr): 3436 (>N-H, stretching), 2244, 
2212 (-C≡N, stretching), 1666 (>C=O, stretching), 
757 (-C-Cl,stretching), 1506 cm−1 (>C=N, stretching); 
1H NMR (400 MHZ, CDCl3): δ, 6.71-8.75 (s, 9H, Ar-
H), 8.25 (s, 2H, Ar-CH=N-), 8.94 (s, 2H, Ar-NH2), 
2.41(s, 2H, Ar-CH3); 13C NMR (100 MHz, DMSO-
d6): δ 169.6, 160.2, 159.4, 152.9, 149.5, 143.4, 137.6, 
137.4, 134.3 (3), 131.2, 129.7, 128.7 (3), 128.2, 
127.4, 127.4, 126.7, 124.9, 115.4 (2), 115.5, 76.7, 
21.5; LCMS: m/z 438.10 (M+). Anal. Calcd for 
C24H15ClN6O C, 65.68; H, 3.45; Cl, 13.00; N, 19.15; 
O, 5.06. Found: C, 65.45; H, 3.22; Cl, 13.01; N, 
19.00; O, 5.04%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-4-(4-methoxyphenyl)-2-oxo-
1,2-dihydropyridine-3,5-dicarbonitrile, 3c: Yield: 
59%. m.p. 255°C. IR (KBr): 3436 (>N-H,stretching), 
2244, 2212 (-C≡N, stretching), 1130,1048 (-C-O-C-, 
stretching) 1666 (>C=O, stretching), 757 (-C-Cl, 
stretching), 1506 cm−1 (>C=N, stretching); 1H NMR 
(400 MHZ, CDCl3): δ, 6.71-8.75 (s, 9H, Ar-H),  
8.25 (s, 1H, Ar-CH=N-), 8.94 (s, 2H, Ar-NH2),  
3.86 (s, 3H, Ar-OCH3); 13C NMR (100 MHz, DMSO-
d6): δ 169.4, 160.0, 159.8, 159.5, 152.7, 149.7, 143.3, 
137.8, 130.1 (2), 131.0, 128.1, 127.8, 127.2, 126.8, 
124.8, 124.3, 115.8(2), 115.3, 114.2 (2), 76.5, 55.8; 
LCMS: m/z 454.87 (M+). Anal. Calcd for 
C24H15ClN6O2 C, 63.37; H, 3.32; Cl, 13.00; N, 18.48; 
O, 7.03. Found: C, 63.31; H, 3.15; Cl, 13.01; N, 




dicarbonitrile, 3d: Yield: 60%. m.p. 259°C. IR 
(KBr): 3436 (>N-H, stretching), 2244, 2212 (-C≡N, 
stretching), 1130, 1048 (-C-O-C-, stretching) 1666 
(>C=O, stretching), 757 (-C-Cl, stretching), 1506 
cm−1 (>C=N, stretching); 1H NMR (400 MHZ, 
CDCl3): δ, 6.71-8.75 (s, 7H, Ar-H), 8.50 (s, 1H, Ar-
CH=N-), 6.49 (s, 2H, Ar-NH2), 3.83 (s, 9H, Ar-
OCH3); 13C NMR (100 MHz, DMSO-d6): δ 169.3, 
160.2, 159.6, 153.1 (2), 152.5, 149.5, 143.2, 138.5, 
137.7, 131.2, 128.2, 127.3, 126.7, 124.4, 115.9 (2), 
115.2, 105.2, 76.6, 56.2 (2), 60.7; LCMS: m/z 514.93 
(M+). Anal. Calcd for C26H19ClN6O4 C, 60.65; H, 
3.72; Cl, 13.00; N, 16.32; O, 12.43. Found: C, 60.51; 
H, 3.55; Cl, 13.01; N, 16.21; O, 12.46%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-4-(3-hydroxyphenyl)-2-oxo-
1,2-dihydropyridine-3,5-dicarbonitrile, 3e: Yield: 
60%. m.p. 262°C. IR (KBr): 3436 (>N-H, stretching), 
2244, 2212 (-C≡N, stretching), 3515 (-O-H, 
stretching), 1666 (>C=O, stretching), 757 (-C-Cl, 
stretching), 1506 cm−1 (>C=N, stretching); 1H NMR 
(400 MHZ, CDCl3): δ, 6.83-9.04 (s, 9H, Ar-H),  
8.49 (s, 1H, Ar-CH=N-), 6.50 (s, 2H, Ar-NH2), 9.45 
(s, 1H, Ar-OH); 13C NMR (100 MHz, DMSO-d6):  
δ 169.3, 160.2, 159.4, 158.3, 152.6, 149.8, 137.9, 
133.8, 131.2, 130.1, 128.3, 127.7, 127.3, 126.9, 124.4, 
121.6, 112.2, 115.6 (2), 115.4, 115.2, 143.4,  
76.6; LCMS: m/z 440.85 (M+). Anal. Calcd for 
C23H13ClN6O2 C, 62.66; H, 2.97; Cl, 13.00; N, 16.32; 
O, 7.26. Found: C, 62.40; H, 2.84; Cl, 13.01; N, 
16.21; O, 7.21%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-4-(4-hydroxyphenyl)-2-oxo-
1,2-dihydropyridine-3,5-dicarbonitrile, 3f: Yield: 
59%. m.p. 245°C. IR (KBr): 3436 (>N-H, stretching), 
2244, 2212 (-C≡N,stretching), 3515 (O-H, stretching), 
1666 (>C=O, stretching), 757 (-C-Cl, stretching), 
1506 cm−1 (>C=N, stretching); 1H NMR (400 MHZ, 
CDCl3): δ, 6.83-9.68 (s, 9H, Ar-H), 8.54 (s, 1H, Ar-
CH=N-), 6.48 (s, 2H, Ar-NH2), 9.67 (s, 1H, Ar-OH); 
13C NMR (100 MHz, DMSO-d6): δ 169.3, 160.2, 
159.3, 158.5, 152.6, 149.8, 143.2, 137.9, 133.7, 131.1, 
130.2, 128.2, 127.7, 127.3, 126.5, 124.4, 121.6, 112.3, 
115.7 (2), 115.2, 115.3, 76.4; LCMS: m/z 440.08 
(M+). Anal. Calcd for C23H13ClN6O2 C, 62.66; H, 
2.97; Cl, 13.00; N, 19.06; O, 7.26. Found: C, 62.42; 
H, 2.82; Cl, 13.01; N, 18.91; O, 7.27%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-4-(3-nitrophenyl)-2-oxo-1,2-
dihydropyridine-3,5-dicarbonitrile, 3g: Yield: 61%. 
m.p. 240°C. IR (KBr): 3436 (>N-H, stretching), 2244, 
2212 (-C≡N, stretching), 1350,1550 (-NO2, 
stretching), 1666 (>C=O, stretching), 757 (-C-Cl, 




stretching), 1506 cm−1 (>C=N, stretching); 1H NMR 
(400 MHZ, CDCl3): δ, 6.83-9.68 (s, 9H, Ar-H), 9.04 
(s, 1H, Ar-CH=N-), 6.49 (s, 2H, Ar-NH2); 13C NMR 
(100 MHz, DMSO-d6): δ 169.5, 160.2, 159.3, 152.8, 
149.9, 147.9, 143.2, 137.9, 135.1, 133.3, 131.2, 129.4, 
128.2, 127.9, 127.1, 126.7, 124.2, 123.3, 120.2, 115.9 
(2), 115.2, 76.5; LCMS: m/z 469.85 (M+). Anal. Calcd 
for C23H12ClN7O3 C, 58.80; H, 2.57; Cl, 13.00; N, 
20.87; O, 10.22. Found: C, 58.69; H, 2.43; Cl, 13.01; 
N, 20.75; O, 10.26%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-4-(4-nitrophenyl)-2-oxo-1,2-
dihydropyridine-3,5-dicarbonitrile, 3h: Yield: 61%. 
m.p. 240°C. IR (KBr): 3436 (>N-H, stretching), 2244, 
2212 (-C≡N, stretching), 1350,1550 (-NO2, 
stretching), 1666 (>C=O, stretching), 757 (-C-Cl 
Stretching), 1506 cm−1 (>C=N, stretching); 1H NMR 
(400 MHZ, CDCl3): δ, 6.83-9.68 (s, 9H, Ar-H), 9.04 
(s, 1H, Ar-CH=N-), 6.49 (s, 2H, Ar-NH2); 13C NMR 
(100 MHz, DMSO-d6): δ 169.3, 160.2, 159.3, 152.5, 
149.6, 147.9, 143.2, 137.9, 135.1, 133.5, 131.1, 129.6, 
128.3, 127.7, 127.3, 126.9, 124.4, 123.2, 120.1, 115.9 
(2), 115.4, 76.4; LCMS: m/z 469.85 (M+). Anal. Calcd 
for C23H12ClN7O3 C, 58.80; H, 2.57; Cl, 13.00; N, 
20.87; O, 10.22. Found: C, 58.67; H, 2.42; Cl, 13.01; 
N, 20.72; O, 10.23%. 
6-amino-1-(((2-chloroquinolin-3-
yl)methylene)amino)-4-(4-fluorophenyl)-2-oxo-1,2-
dihydropyridine-3,5-dicarbonitrile, 3i: Yield: 62%. 
m.p. 251°C. IR (KBr): 3436 (>N-H, stretching), 2244, 
2212 (-C≡N,stretching), 945 (-C-F, stretching), 757  
(-C-Cl, stretching), 1666 (>C=O, stretching), 1506 
cm−1 (>C=N, stretching); 1H NMR (400 MHZ, 
CDCl3): δ, 6.83-9.68 (s, 9H, Ar-H), 9.02 (s, 1H, Ar-
CH=N-), 6.55 (s, 2H, Ar-NH2); 13C NMR (100 MHz, 
DMSO-d6): δ 169.3, 160.1, 159.4, 156.7, 152.9, 
149.8, 137.9, 131.2, 129.6, 128.2, 128.1, 127.9, 127.3, 
126.9, 124.4, 124.3, 121.8, 115.7 (2), 115.2, 115.4, 
143.5, 76.6; LCMS: m/z 442.84 (M+). Anal. Calcd for 
C23H12ClFN6O C, 62.38; H, 2.73; Cl, 13.00; N, 18.98; 
O, 3.61. Found: C, 62.21; H, 2.64; Cl, 13.01; N, 
18.77; O, 3.58%. 
6-amino-4-(2-chlorophenyl)-1-(((2-
chloroquinolin-3-yl)methylene)amino)-2-oxo-1,2-
dihydropyridine-3,5-dicarbonitrile, 3j: Yield: 60%. 
m.p. 247°C. IR (KBr): 3436 (>N-H, stretching), 2244, 
2212 (-C≡N,stretching), 757 (-C-Cl, stretching), 1666 
(>C=O, stretching), 1506 cm−1 (>C=N, stretching); 
1H NMR (400 MHZ, CDCl3): δ, 6.83-9.68 (s, 9H, Ar-
H), 8.51 (s, 1H, Ar-CH=N-), 6.48 (s, 2H, Ar-NH2); 
13C NMR (100 MHz, DMSO-d6): δ 169.3, 160.0, 
159.6, 156.7, 152.8, 149.6, 137.6, 131.0, 129.6, 128.2, 
128.1, 127.9, 127.3, 126.9, 124.2, 124.3, 121.8, 115.9 
(2), 115.3, 115.4, 143.5, 76.6; LCMS: m/z 459.29 
(M+). Anal. Calcd for C23H12Cl2N6O C, 60.15; H, 
2.63; Cl, 13.00; N, 18.30; O, 3.48. Found: C,60.04; H, 
2.45; Cl, 13.01; N, 18.20; O, 3.44%. 
 
Conclusion 
Discussion presented over here indicates that 
compounds 3a-j can be synthesized by a simple 
synthetic path without formation of any side products. 
Further, among these newly synthesized molecules, 
compound 3i exhibited excellent antibacterial potential 
and compound 3e is found to have excellent antifungal 
capacity. Aforesaid structure activity relationship 
studyrecommends that presence of electron-donating 
functional groups and presence of –OH group on meta 
position as substituents in compounds 3a-j is responsible 
for prominent antibacterial and antifungal potential 
respectively. Hence further modification of these novel 
molecules (3i and 3e) constructed by bridging quinoline 
and 2-pyridone molecules may be useful to identify lead 
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